Compare Kroger Co (KR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Sana Biotechnology Inc — how do they compare? Kroger Co trades at $61.64 (market cap $36.27B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Kroger Co is far larger — about 43.3× Sana Biotechnology Inc's market cap, and Kroger Co pays a 2.54% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Sana Biotechnology Inc for 23 Days on average.
| KR | SANA | |
|---|---|---|
Market Cap | $36.27B | $836.71M |
Volume | 8,301,523 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $5.92 |
52-Week Low | $55.53 | $2.68 |
Typical Hold Time | 108 Days | 23 Days |
Enterprise Value | $57.69B | $749.96M |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.41, up 3.65% with a bullish technical outlook. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, though net margin remains thin at 0.73%. Recent earnings beat expectations in Q2 2026, and the company maintains consistent dividends. Analysts are moderately bullish with a $70.62 consensus target, citing digital growth and operational improvements as key drivers.
KR offers value with low P/S (0.26) and stable cash flow generation, but faces risks from competitive pressures and integration challenges from acquisitions. The stock presents opportunity for investors seeking defensive exposure with dividend income, though margin compression and economic sensitivity warrant caution.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
